glp-1 agonists blindness risk The Effect of Semaglutide and RAs on of Nonarteritic Anterior Ischemic Optic Neuropathy Eye doctors warn GLP-1 drugs
Description
& Jerlhag, E
While not approved specifically for weight loss, clinical trials showed average weight reduction of 3-5% of body weight, making it the least potent option in this category for weight management
A robust sandwich covariance matrix estimator was used in the Cox model analyses to account for the re-use of stable use sets of insulin in the matching for GLP-1RA users (Additional file 1: Fig
We only include drugs in development that have reported effects on weight loss
"FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight"
